BUZZ-Preview: Goldman Sachs third-quarter earnings per share and revenue expected to grow
路透社2026/10/12 18:51October 12 - ** Goldman Sachs (GS) shares fell 0.6% on Monday to $890.26, as the market awaits the release of its quarterly earnings before the bell, with investors focused on revenue trends.
** According to predictions from the London Stock Exchange Group (LSEG), the global investment bank is expected to report a 10% year-over-year increase in quarterly revenue to $16.71 billion, with adjusted earnings per share at $13.02, higher than $12.25 in the same period last year.
** Goldman Sachs has beaten earnings per share estimates for at least the past eight quarters; in seven out of the past eight quarters its revenue met or exceeded expectations, with the last miss occurring in Q4 2025.
** Of the 25 analysts covering Goldman Sachs, ratings are distributed as follows: 9 give a “Strong Buy” or “Buy” rating, 15 give a “Hold” rating, and 1 issues a “Strong Sell” rating.
** The median price target is $1,130, lowered from $1,175 a month ago.
** Goldman Sachs shares have risen 1.3% year-to-date, while the Dow Jones Industrial Average is up 7.8% over the same period .DJI
(To facilitate non-English speakers, Reuters has automatically translated this report into several other languages. As automated translations may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of the automated translation, which is provided solely for the convenience of readers. Reuters accepts no liability for any damage or loss caused by the use of automated translation functionality.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results
Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.
Kroger (KR.US) faces the largest layoffs in 143 years: cutting one-third of positions, more than 3,000 employees to be let go
Kroger has laid off 3,000 employees, accounting for more than one-third of its total workforce, marking the largest layoff in its 143-year history. The resources saved will be redirected towards price reductions and frontline operations.
RBA Minutes: Case for rates to act promptly to keep inflation expectations anchored